Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen Reports Loss, Increased Revenues for Q1

NEW YORK, May 16 - Deltagen, after downsizing the company earlier this year, reported increased revenues for the first quarter yesterday.


The company had revenues of $4.6 million for the first quarter, compared to $2.6 million during the same period last year. Its losses in the first quarter totaled $18.0 million, slightly down from $18.7 million a year ago. This includes $9.3 million in restructuring charges related to the downsizing of the company.


Deltagen's R&D expenses decreased significantly to $10.1 million, down from $16.8 million for the first quarter of last year.


In April, Deltagen secured a bridge loan of $5 million as well as a private placement of $10 million from existing institutional investors.


As of March 31, the company had $2.7 million in cash, cash equivalents, and marketable securities, compared to $13.8 million at the end of December, 2002.


The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.